AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (Original): The use of 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-ethyl-4-(2-phenoxyethyl)-2H-1,2,4-triazol-3(4H)-one (nefazodone) or of a pharmaceutically acceptable salt thereof for producing medicaments for the treatment of Parkinson's disease.

Claim 2 (Amended): The use of 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-1,2,4-triazolo[4,3-a]pyridin-3(2H)-one (trazodone) or of a pharmaceutically acceptable salt thereof and of 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-ethyl-4-(2-phenoxyethyl)-2H-1,2,4-triazol-3(4H)-~~5-ethyl-4-(2-phenoxyethyl)-2H-1,2,4-triazol-3(4H)-one~~ one (nefazodone) or of a pharmaceutically acceptable salt thereof for producing medicaments for the treatment of Parkinson's disease.

Claim 3 (Original): The use of cetirizine or of a pharmaceutically acceptable salt thereof for producing medicaments for the treatment of Parkinson's disease.

Claim 4 (Original): The use as claimed in claim 3, characterized in that the latter includes cetirizine dihydrochloride.

Claim 5 (Amended): The use as claimed in claim 3 ~~or 4~~, characterized in that the medicament includes a single dose of cetirizine of at least about 5 mg, preferably at least about 10 mg.

Claim 6 (Amended): The use as claimed in ~~any of claims 3, 4 or 5,~~claim 3, characterized in that the cetirizine is in tablet form or in the form of a solution or suspension.

Claim 7 (Amended): The use as claimed in claim 2, in which the composition comprising the trazodone or a pharmaceutically acceptable salt thereof is intended for intake in the evening.

Claim 8 (Amended): The use as claimed in ~~either of claims 2 or 7,~~claim 2, in which the medicament is in tablet form, where the tablet intended for a single dose comprises between about 50 mg and about 200 mg of one of the active substances nefazodone or trazodone or in each case a corresponding dose of both active substances.

Claim 9 (Amended): The use as claimed in ~~any of claims 2, 7 or 8~~claim 2 for producing medicaments for the treatment of depression in parkinsonian patients.

Claim 10 (Amended): The use as claimed in ~~any of~~ claim~~s~~ 1~~to 9~~ in patients simultaneously treated with L-dopamine.

Claim 11 (Amended): The use as claimed in ~~claim 3 or 4,~~claim 1, characterized in that a daily dose totaling between about 100 mg and about 800 mg, where appropriate in a plurality of single doses, is administered to the patient.

Claim 12 (Amended): The use as claimed in ~~any of the preceding claims,~~claim 1, characterized in that a daily dose of between about 300 and about 600 mg is administered to the patient.

Claim 13 (Amended): The use as claimed in ~~any of the preceding claims,~~claim 1, characterized in that the nefazodone or its pharmaceutically acceptable salt is administered in two to three single doses.

Claim 14 (Amended): The use as claimed in ~~any of the preceding claims,~~claim 1, characterized in that the nefazodone or its pharmaceutically acceptable salt is administered in one or more single doses each of about 100 mg to about 200 mg.

Claim 15 (Amended): The use as claimed in ~~any of the preceding claims,~~claim 1, characterized in that the nefazodone or its pharmaceutically acceptable salt is administered in tablet form intended for oral intake.

Claim 16 (Amended): The use as claimed in ~~any of the preceding claims~~claim 1, in conjunction with intake of a caffeine- and/or acetylsalicylic acid-containing composition in the same period for the treatment of Parkinson's disease.

Claim 17 (Amended): A pharmaceutical active substance combination comprising 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-ethyl-4-(2-phenoxyethyl)-2H-1,2,4-triazol-3(4H)-one (nefazodone) or a pharmaceutically acceptable salt thereof and 2-[3-[4-(3-chlorophenyl)-1-~~2-[3-[4-(3-chlorophenyl)-1-~~piperazinyl]propyl]-1,2,4-triazolo[3,4-a]pyridin-3(2H)-one (trazodone) as combination product for simultaneous, separate or sequential use in the therapy of Parkinson's disease.

Claim 18 (Amended): The pharmaceutical active substance combination as claimed in claim 17 comprising at least one antihistamine or a pharmaceutically acceptable salt thereof besides nefazodone or trazodone

as combination product for simultaneous, separate or sequential use in the therapy of Parkinson's disease.

Claim 19 (Original): The pharmaceutical active substance combination as claimed in claim 18, characterized in that the latter includes cetirizine or one of its pharmaceutically acceptable salts as antihistamine.

Claim 20 (Amended): The pharmaceutical active substance combination as claimed in ~~any of claims 17 to 19,~~claim 17, characterized in that at least the nefazodone/trazodone is in tablet form, where a tablet intended for a single dose comprises between about 50 mg and about 200 mg of at least one of the active substances nefazodone and/or trazodone or in each case a corresponding dose of both active substances.

Claim 21 (Amended): The pharmaceutical active substance combination as claimed in ~~any of claims 18 to 20,~~claim 18, characterized in that the antihistamine includes cetirizine or its hydrochloride.

Claim 22 (Amended): The pharmaceutical active substance combination as claimed in ~~any of claims 18 to 21,~~claim 21, characterized in that cetirizine or one of its pharmaceutically acceptable salts is in tablet form, and a single dose comprises at least about 5 mg, preferably at least about 10 mg, of this active substance.

Claim 23 (New): The use as claimed in any of claim 2 in patients simultaneously treated with L-dopamine.

Claim 24 (New): The use as claimed in any of claim 3 in patients simultaneously treated with L-dopamine.

Claim 25 (New): The use as claimed in claim 2, characterized in that a daily dose totaling between about 100 mg and about 800 mg, where appropriate in a plurality of single doses, is administered to the patient.

Claim 26 (New): The use as claimed in any of claim 2, characterized in that a daily dose of between about 300 and about 600 mg is administered to the patient.

Claim 27 (New): The use as claimed in any of claim 2, characterized in that the nefazodone or its pharmaceutically acceptable salt is administered in two to three single doses.

Claim 28 (New): The use as claimed in any of claims 2, characterized in that the nefazodone or its pharmaceutically acceptable salt is administered in one or more single doses each of about 100 mg to about 200 mg.

Claim 29 (New): The use as claimed in any of claims 2, characterized in that the nefazodone or its pharmaceutically acceptable salt is administered in tablet form intended for oral intake.

Claim 30 (New): The use as claimed in any of claims 2 in conjunction with intake of a caffeine- and/or acetylsalicylic acid-containing composition in the same period for the treatment of Parkinson's disease.

Claim 31 (New): The use as claimed in any of claims 3 in conjunction with intake of a caffeine- and/or acetylsalicylic acid-containing composition in the same period for the treatment of Parkinson's disease.